Good morning, Madam Chair and honourable members of the committee. Thank you for having me.
I'm Kevin Outterson, a professor at Boston University and the founding executive director of CARB-X. We're the largest non-profit initiative in the world that supports and translates early-stage development of innovative products to treat, prevent and diagnose bacterial infections. We have been a recipient of funding from the Canadian government since 2023, and we are very grateful for this support.
Today, I am going to focus on Canada’s role in financing a complementary mix of push and pull incentives for new antibiotics that will help drive and grow private sector investment in research and development in Canada, in addition to addressing the public health need both in Canada and around the world for new antibiotics now.
As you may well be aware, given the concern about antimicrobial resistance, or AMR, the market for antibiotics is broken. This is a product that comes to the market, and we want to use it as little as possible in the first several years. That's great for public health, but it's a disaster for small companies. We need both push and pull incentives, grant-based things that happen before approval and also something that happens after approval and it reaches the market, to make these products available to everyone, especially to Canadians who, in my prior academic work, came in dead last amongst the G7 in terms of access to new antibiotics.
We want to also encourage more private sector activity in this area. We're non-profit, but we work with all of the private sector companies that do this research.
Two years ago, I served as an international member of the expert panel for the Council of Canadian Academies project that led to the report called “Overcoming Resistance”, building on prior work by CCA and the pan-Canadian action plan. This is a great report. The consensus is clear. It says that, without new incentives, the antibiotic pipeline is going to be perilously thin and that Canadians are going to lack access, worse than any other G7 country.
Second, the report said that, if you do both push and pull incentives, you are going to restore health to the pipeline. Canada can be a leader within the G7 on this issue, and you can protect the foundation of modern medicine. You wouldn't have a knee replacement or many cancer treatments; they would be less safe and more dangerous if you didn't have the safety net of antibiotics.
These incentives work in different ways against the same problem. They work together and are both essential. Canada has already been acting on this. The Public Health Agency of Canada invested in CARB-X two years ago. We're grateful for that.
CARB-X is currently supported by six G7 governments, including Canada, and three private foundations: Wellcome, Gates and Novo, as well as the European Commission, who will be announcing their support for us later in the year.
This important role was mentioned four times in the last G7 health ministers' communiqué and also in the G20. It was also mentioned at the UN General Assembly's high-level meeting on antimicrobial resistance last year. We've had 22 products make it to human clinical trials. Three have reached the market, which is remarkable, given how thin the pipeline is.
We're really grateful for the partnership with the Canadian government, which was historically represented by PHAC, the Public Health Agency of Canada, but is now transitioning to health emergency readiness Canada, HERC, which will continue at a level that is commensurate, we hope, with other G7 governments. Considering what other governments are giving us, the Canadian amount would be something like $6 million per year. The U.S. government is contributing $55 million, for example. Germany gives $15 million, and Italy contributes $12 million.
The push incentives, like what you did with CARB-X, lower the cost of R and D. Obviously we think they're useful, but we also need pull incentives. The “Overcoming Resistance” report has a very important pilot program on pull incentives, a revenue guarantee across Canada. This is very valuable, and it is important that we get that right, when the pilot comes out, for it to be effective in working with the market so that Canadians have access and research development is supported.
Canada’s science community is world class. A colleague of mine, Professor Gerry Wright from McMaster, is also testifying at this hearing at some point in the future. He is one of the leading researchers of the world. A recent important paper in Nature came out of a discovery in his lab. He told me—and said I could share with you—that out of the 87 trainees, post-docs, Ph.D. students and techs who have worked in his lab in the decades that he has been working at McMaster, today, only seven of them are still working in antimicrobial resistance.
There's a human capital problem, and there's a pipeline problem. They need to be solved by a combination of push and pull. I'm grateful for what Canada is doing to make that happen.
Thank you.
